Clinical trials

The Statista dossier
  • Detailed references
  • Editorially prepared
  • Download as PDF / PPT

Statista dossier about clinical research

This dossier presents key facts and figures about clinical trials worldwide, with a focus on the United States. Clinical trials are also known as Phase I to IV within the research, development, and approval process for new drugs, medical devices, or procedures. This document gives you an overview about health R&D in general, number of clinical studies, success rates, costs, and many more.

Table of contents

  • 1. R&D overview
    • Total global pharmaceutical R&D spending 2010-2024

    • Industry sectors - expenditure on research and development 2012-2016

    • Top pharmaceutical R&D projects based on net present value May 2018

    • Research and development expenditure: U.S. pharmaceutical industry 1995-2017

    • Research and development in European pharmaceutical industry by country 2016

    • Total clinical research funding by National Institutes for Health 2013-2018

  • 2. Top R&D companies
    • Global top pharmaceutical companies based on R&D spending 2024

    • Top 50 global pharmaceutical and biotech companies by R&D intensity in 2016/2017

    • Top pharmaceutical companies in R&D spending growth 2016-2017

    • Roche: participation of patients in clinical trials 2009-2017

    • Leading global contract research organizations based on revenue 2017

    • Investments made by clinical research organizations by phase 2009-2014

  • 3. Clinical studies
    • Comparison between the complexity of clinical trials 2001-2015

    • Increase in clinical trials' complexity 2001-2015

    • Number of registered clinical studies by location worldwide 2018

    • Percent of registered clinical studies worldwide by location 2018

    • Share of recruiting clinical studies worldwide by location 2018

    • Total number of registered clinical studies worldwide since 2000

    • Total number of registered clinical studies with posted results worldwide 2009-2017

  • 4. Success rates
    • U.S. drug development Phase success rates 2006-2015

    • U.S. drug development Phase II success rates 2006-2015, by disease area

    • U.S. drug development Phase III success rates from 2006 to 2015, by disease area

    • U.S. development Phase success rates for oncology and non oncology drugs 2006-2015

    • U.S. drug development Phase success rates, by drug classification 2006-2015

    • U.S. development phase success rates for drugs with and without biomarkers 2006-2015

  • 5. Costs
    • Pharmaceuticals: cost of drug development in the U.S. since 1975

    • Leading orphan drugs based on R&D phase III cost 2015

    • Average per-study costs by trial phase

    • Total per-study costs by clinical trial phase and therapeutic area

    • Clinical trial costs by select component and phase

    • Average per-patient clinical trial costs in U.S. 2013, by selected condition

    • Average per-patient biopharmaceutical clinical trial costs in the U.S. 2013, by phase

  • 6. Approvals, launches, setbacks
    • Number of new drugs launched in the U.S. 2003-2015

    • Pharmaceutical industry - number of new substances 1992-2017

    • First world new molecular entities launched 2004-2015

    • FDA first premarket approvals for medtech products granted 2005-2017

    • NDA/BLA filing to FDA approval times for new drugs in select disease areas 2006-2015

    • Number of unsuccessful Alzheimer’s drugs in development in the U.S. 1998-2014

    • Unsuccessful developing melanoma drugs in the U.S. 1998-2014

    • Unsuccessful developing lung cancer drugs in the U.S. 1998-2014

  • Language: English
  • Released: August 2017
More than 7,500
Recommended studies and dossiers
Show more
Recent studies and dossiers
You may also be interested in...
Statista is a great source of knowledge, and pretty helpful to manage the daily work.

Christof Baron about Statista CEO, MindShare Germany

Any more questions?

Get in touch with us quickly and easily. We are happy to help!